Case number 1:19-cv-00071
Onyx Therapeutics, Inc. v. Breckenridge Pharmaceutical, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 16, 2019 | 18 | Order (3) Docket Text: CONSENT JUDGMENT as to Breckenridge Pharmaceutical Inc., ***Civil Case Terminated. Signed by Judge Leonard P. Stark on 5/14/19. Associated Cases: 1:16-cv-01001-LPS, 1:18-cv-00262-LPS, 1:19-cv-00071-LPS (ntl) |
| May 10, 2019 | 17 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT - Breckenridge Pharmaceutical, Inc. by Onyx Therapeutics, Inc.. (Jacobs, Karen) |
| Apr 12, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [16] MOTION for Pro Hac Vice Appearance of Attorney James K. Stronski, Chiemi D. Suzuki and Jacob Z. Zambrzycki of Crowell & Moring LLP filed by Breckenridge Pharmaceutical, Inc. Signed by Judge Leonard P. Stark on 4/12/19. (ntl) |
| Apr 10, 2019 | 16 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney James K. Stronski, Chiemi D. Suzuki and Jacob Z. Zambrzycki of Crowell & Moring LLP - filed by Breckenridge Pharmaceutical, Inc.. (Metzler, Sara) |
| Mar 8, 2019 | 15 | Redacted Document (30) Docket Text: REDACTED VERSION of [13] Answer to Complaint, Counterclaim and affirmative defenses by Breckenridge Pharmaceutical, Inc.. (Metzler, Sara) |
| Mar 4, 2019 | N/A | SO ORDERED (0) |
| Mar 4, 2019 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:16-cv-00988-LPS. (ntl) |
| Mar 1, 2019 | N/A | SO ORDERED (0) |
| Mar 1, 2019 | 14 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pensa Pharma S.A. for Breckenridge Pharmaceutical, Inc. filed by Breckenridge Pharmaceutical, Inc.. (Farnan, Kelly) |
| Feb 28, 2019 | 11 | Stipulation (3) Docket Text: Joint STIPULATION to streamline issues for discovery and trial by Onyx Therapeutics, Inc.. (Dellinger, Megan) |
| Feb 28, 2019 | 12 | Stipulation (4) Docket Text: Joint STIPULATION regarding consolidation with C.A. No. 16-988 by Onyx Therapeutics, Inc.. (Dellinger, Megan) |
| Feb 26, 2019 | 10 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to move, answer or otherwise respond to the Complaint to and including March 1, 2019 - filed by Breckenridge Pharmaceutical, Inc.. (Metzler, Sara) |
| Feb 25, 2019 | N/A | SO ORDERED (0) |
| Feb 19, 2019 | 9 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to move, answer or otherwise respond to the Complaint to and including February 26, 2019 - filed by Breckenridge Pharmaceutical, Inc.. (Farnan, Kelly) |
| Feb 14, 2019 | N/A | SO ORDERED (0) |
| Feb 14, 2019 | 8 | Affidavit of Service (9) Docket Text: AFFIDAVIT of Service for Summons, Complaint and related papers served on Robert F. Vroom on February 1, 2019, filed by Onyx Therapeutics, Inc.. (Jacobs, Karen) |
| Feb 12, 2019 | 7 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to move, answer or otherwise respond to the Complaint to and including February 19, 2019 - filed by Breckenridge Pharmaceutical, Inc.. (Farnan, Kelly) |
| Jan 16, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Jan 11, 2019 | 1 | Complaint (16) |
| Jan 11, 2019 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Breckenridge Pharmaceutical, Inc. on 1/11/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (lak) |
| Jan 11, 2019 | 1 | Exhibit A-C (107) |
| Jan 11, 2019 | 1 | Civil Cover Sheet (2) |
| Jan 11, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lak) |
| Jan 11, 2019 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/29/2018. Date of Expiration of Patent: See attachment.Thirty Month Stay Deadline: 5/29/2021. (lak) |
| Jan 11, 2019 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,417,042 B2 ;7,737,112 B2 ;8,207,125 B2. (lak) |
| Jan 11, 2019 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Amgen, Inc., Corporate Parent Onyx Pharmaceuticals, Inc. for Onyx Therapeutics, Inc. filed by Onyx Therapeutics, Inc. (lak) |
| Jan 11, 2019 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Onyx Therapeutics, Inc.. Breckenridge Pharmaceutical, Inc. served on 1/11/2019, answer due 2/1/2019. (Blumenfeld, Jack) |
| Jan 11, 2019 | 1 | Main Document (16) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT - filed against Breckenridge Pharmaceutical, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2542117.) - filed by Onyx Therapeutics, Inc. (Attachments: # (1) Exhibit A-C, # (2) Civil Cover Sheet)(lak) |
